SCHEMBL1897308

SCHEMBL1897308

COCCNc1cc(OCCN(C)C)ccc1C(=O)Nc1nn(C(=O)OC)c2c1CN(S(=O)(=O)c1cc(F)cc(F)c1)CC2

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 3/20 0.39
INSR P06213 2/20 0.36
ALK Q9UM73 2/20 0.36
AURKA O14965 1/20 0.36
AURKB Q96GD4 1/20 0.36
LSS P48449 1/20 0.34
USP9X Q93008 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
FGFR4 P22455 2/20 0.32
AKR1C3 P42330 1/20 0.32
MGLL Q99685 1/20 0.32
ABHD6 Q9BV23 1/20 0.32
BRAF P15056 1/20 0.31
BACE1 P56817 1/20 0.31
LMNA P02545 2/20 0.31
ALDH1A1 P00352 2/20 0.31
AXL P30530 1/20 0.31
KDM4E B2RXH2 1/20 0.31
SLC6A9 P48067 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1898473 0.96 IGF1R (0.37) IGF1RINSRALKAURKAAURKB
SCHEMBL1907344 0.95 IGF1R (0.37) IGF1RINSRALKAURKAAURKB
SCHEMBL4323676 0.95 IGF1R (0.40) IGF1RINSRALKAURKAAURKB
SCHEMBL1433760 0.95 IGF1R (0.37) IGF1RINSRALKAURKAAURKB
SCHEMBL1895374 0.91 IGF1R (0.40) IGF1RINSRALKAURKAAURKB
SCHEMBL1896784 0.90 INSR (0.38) IGF1RINSRALKLSSUSP9X
SCHEMBL1434090 0.90 INSR (0.38) IGF1RINSRALKLSSUSP9X
SCHEMBL1434093 0.90 INSR (0.38) IGF1RINSRALKLSSUSP9X
SCHEMBL1433659 0.89 IGF1R (0.39) IGF1RINSRALKAURKAAURKB
SCHEMBL1433615 0.88 INSR (0.42) IGF1RINSRALKAURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8809337-B2 Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-08-19 US claimed
US-20130203770-A1 CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-08-08 US claimed
US-20110118278-A1 CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-19 US claimed
US-8809337-B2 Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-08-19 US disclosed
US-20130203770-A1 CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-08-08 US disclosed
US-20110118278-A1 CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203770-A1 CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS DMPK, DCK, MAP3K19 IGF1R 1797/4885INSR 1921/4885ALK 158/4885
US-20110118278-A1 CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS DMPK, DCK, MAP3K19 IGF1R 1797/4885INSR 1921/4885ALK 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.